Integra Lifesciences Holdings Corp  

(Public, NASDAQ:IART)   Watch this stock  
Find more results for IART
-1.06 (-1.72%)
Mar 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 59.94 - 61.51
52 week 42.50 - 62.99
Open 61.21
Vol / Avg. 0.00/180,154.00
Mkt cap 2.02B
P/E 58.88
Div/yield     -
EPS 1.03
Shares 32.78M
Beta 0.91
Inst. own 80%
May 20, 2015
Integra LifeSciences Holdings Corp Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
Apr 29, 2015
Q1 2015 Integra LifeSciences Holdings Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 24, 2015
Integra LifeSciences Holdings Corp at Canaccord Genuity Musculoskeletal Conference
Mar 12, 2015
Integra LifeSciences Holdings Corp at Barclays Healthcare Conference
Mar 2, 2015
Integra LifeSciences Holdings Corp at Raymond James Institutional Investors Conference
Feb 25, 2015
Integra LifeSciences Holdings Corp at RBC Healthcare Conference
Feb 24, 2015
Q4 2014 Integra LifeSciences Holdings Corp Earnings Release
Feb 24, 2015
Q4 2014 Integra LifeSciences Holdings Corp Earnings Call - Webcast
Jan 14, 2015
Integra LifeSciences Holdings Corp at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 6.81% 3.66%
Operating margin 10.58% 7.06%
EBITD margin - 13.65%
Return on average assets 4.41% 2.45%
Return on average equity 9.90% 4.96%
Employees 3,400 -
CDP Score - -


311 Enterprise Dr
PLAINSBORO, NJ 08536-3344
United States - Map
+1-609-2750500 (Phone)
+1-609-2755363 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Integra LifeSciences Holdings Corporation operates in medical technology. Integra offers solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. Integra was founded on a technology platform to repair and regenerate tissue with engineered collagen devices. The Company develops product lines for applications ranging from burn and deep tissue wounds to regeneration of Dura mater in the brain and repair of nerve and tendon. The Company manufactures and sells products in five business segments: U.S. Neurosurgery, U.S. Extremities, U.S. Instruments, U.S. Spine and Other, and International. The Company�s products include regenerative medicine implants, metal implants, instruments and equipment for orthopedic surgery, neurosurgery and general surgery. The U.S. Neurosurgery segment sells a line of products for neurosurgery and neuro critical care. The U.S. Instruments segment is a surgical instrument supplier in the United States.

Officers and directors

Stuart M. Essig Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Peter J. Arduini President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Glenn G. Coleman Chief Financial Officer, Principal Accounting Officer, Corporate Vice President
Age: 46
Bio & Compensation  - Reuters
Padma Thiruvengadam Chief Human Resources Officer, Corporate Vice President
Age: 49
Bio & Compensation  - Reuters
Kenneth E. Burhop Ph.D. Chief Scientific Officer, Corporate Vice President
Bio & Compensation  - Reuters
Judith E. O'Grady Corporate Vice President - Global Regulatory Affairs, Corporate Compliance Officer
Age: 63
Bio & Compensation  - Reuters
John Mooradian Corporate Vice President - Global Operations and Supply Chain
Age: 58
Bio & Compensation  - Reuters
Richard D. Gorelick Corporate Vice President, General Counsel, Administration, Secretary
Age: 53
Bio & Compensation  - Reuters
Jerry E. Corbin Corporate Vice President, Corporate Controller
Age: 53
Bio & Compensation  - Reuters
Mark A. Augusti Corporate Vice President, President, Orthopedics and Tissue Technologies
Bio & Compensation  - Reuters